Myriad Genetics, Inc. (MYGN) recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).The latest collaboration should help Myriad Genetics strengthen its market presence and broaden patients’ access to the benefits of MRD testing.About MRD TestMRD tests are blood-based diagnostic tools that enable clinicians to monitor therapeutic responses to cancer treatment more closely than with traditional cancer de ...

Myriad Genetics, Inc. (MYGN) recently secured a second foundational patent from the United States Patent and Trademark Office that bolsters its abilities to launch a tumor-informed, high-definition, molecular residual disease (MRD) assay. U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers the company’s breakthrough platform MRD technology, which enables highly sensitive and specific tumor-informed, sequencing-based MRD assays such as Precise MRD.The latest development reveals another ...

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent no. 12,024,749, entitled "Combinatorial DNA Screening," covers Myriad's groundbreaking platform MRD technology, which enables highly sen ...

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it's a Great Place To Work – 27 percentage points higher than the average U.S. company. "It's rare to work somewhere where everyone ...

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it’s a Great Place To Work – 27 percentage points higher than the average U.S. company. “It’s rare to work somewhere where everyone ...

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. “The results of the Special Election Survey show that politics and elections tend to trouble our nation’s mental wellbeing,” said Thomas J. Valente, a psychiatrist f ...

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. “The results of the Special Election Survey show that politics and elections tend to trouble our nation’s mental wellbeing,” said Thomas J. Valente, a psychiatrist f ...

Myriad Genetics, Inc. (MYGN) recently announced a collaboration with GSK plc (GSK) to advance in the field of genetic testing. The latest development is intended to improve access to homologous recombination deficiency (HRD) diagnostic testing for high-grade ovarian cancer (HGSOC) patients.With this alliance, Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests, collectively known as Myriad's MyChoice Tests, are now part of a new sponsored testing program that is accessible in Argentina, Brazil, Chile, Co ...

文章核心观点 - 公司的产品组合和增长策略令人乐观 [1][2][3][4][5][6][7] - 但宏观经济问题阻碍了公司的增长 [10][11][12][13] 公司发展情况 产品和服务 - 公司在遗传性癌症市场持续增加份额,myRisk产品被医疗服务提供商广泛采用 [3] - 公司计划推出Foresight Universal Plus扩展型携带者筛查测试和FirstGene产前筛查测试 [9] - 公司获得了一项有助于推出高清MRD检测产品的专利 [8] 战略合作 - 公司与Illumina扩大合作,以拓展生物制药业务并提高HRD检测在美国的覆盖面 [4] - 公司与日本国立癌症中心东医院合作,研究MRD检测的预后和预测价值 [5] 运营管理 - 公司保持严格的成本管控,毛利率保持较高水平 [6][7] - 公司致力于提升客户体验,包括开发新的技术工具和能力、创新、商业能力和实验室升级 [6] 行业挑战 - 国际贸易恶化和全球通胀压力导致原材料、人工成本和运费上升,对公司盈利能力造成压力 [10][11] - 汇率波动也给公司带来风险,公司尚未采取对冲策略 [12][13][14]

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad's MyChoice Tests) is now available in Argentina, Braz ...